1. Ashina M, Terwindt GM, Al-Karagholi MAM, de Boer I, Lee MJ, Hay DL, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021;397(10283):1496-1504. doi:10.1016/S0140-6736(20)32162-0 PMid:33773610

2. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, et al. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi:10.1186/s10194-020-01208-0 PMid:33267788 PMCid:PMC7708887

3. Onofri A, Pensato U, Rosignoli C, Wells-Gatnik W, Stanyer E, Ornello R, et al. Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis. J Headache Pain. 2023;24(1):8. doi:10.1186/s10194-023-01541-0 PMid:36782182 PMCid:PMC9926688

4. Olesen J. Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders. Cephalalgia. 2018;38(1):1-211. doi:10.1111/j.1468-2982.2008.01709.x PMid:19126115

5. Patniyot I, Qubty W. Headache in adolescents. Neurol Clin. 2023;41(1):177-192. doi:10.1016/j.ncl.2022.08.001 PMid:36400554

6. Abu-Arafeh I, Morozova M. Migraine in children and adolescents: assessment and diagnosis. Handb Clin Neurol. 2024;199:475-485. doi:10.1016/B978-0-12-823357-3.00029-X PMid:38307664

7. Wöber-Bingöl Ç. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17(6):341. doi:10.1007/s11916-013-0341-z PMid:23700075 PMCid:PMC9799295

8. Steinmetz JD, Seeher KM, Schiess N, Nichols E, Cao B, Servili C, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344-381. doi:10.1016/S1474-4422(24)00038-3 PMid:38493795 PMCid:PMC10949203

9. Lu G, Xiao S, Wang Y, Jia Q, Liu S, Yu S, et al. Global epidemiology and burden of headache disorders in children and adolescents from 1990 to 2021. Headache. 2025;65(7):1170-1179. doi:10.1111/head.14937 PMid:40172214

10. Mohammadi P, Khodamorovati M, Vafaee K, Hemmati M, Darvishi N, Ghasemi H. Prevalence of migraine in Iran: a systematic review and meta-analysis. BMC Neurol. 2023;23(1):172. doi:10.1186/s12883-023-03215-5 PMid:37106419 PMCid:PMC10134641

11. Togha M, Rafiee P, Ghorbani Z, Khosravi A, Şaşmaz T, Akıcı Kale D, et al. The prevalence of headache disorders in children and adolescents in Iran: a schools-based study. Cephalalgia. 2022; 42(11-12):1246-1254. doi:10.1177/03331024221103814 PMid:35818307

12. Fallahzadeh H, Alihaydari M. Prevalence of migraine and tension-type headache among school children in Yazd, Iran. J Pediatr Neurosci. 2011;6(2):106-109. doi:10.4103/1817-1745.92818 PMid:22408655 PMCid:PMC3296400

13. Ayatollahi SMT, Khosravi A. Prevalence of migraine and tension-type headache in primary-school children in Shiraz. East Mediterr Health J. 2006; 12(6):809-817.

14. Togha M, Rafiee P, Haghdoost F, Rafie S, Paknejad SMH, Amouian S, et al. The burdens attributable to primary headache disorders in children and adolescents in Iran: estimates from a schools-based study. J Headache Pain. 2024;25(1):86. doi:10.1186/s10194-024-01789-0 PMid:38797825 PMCid:PMC11129382

15. Özge A, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, et al. Experts' opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta. J Headache Pain. 2017;18(1):113. doi:10.1186/s10194-017-0819-x PMid:29285571 PMCid:PMC5745369

16. Arruda MA, Bigal ME. Behavioral and emotional symptoms and primary headaches in children: a population-based study. Cephalalgia. 2012; 32(15):1093-1100. doi:10.1177/0333102412454226 PMid:22988005

17. Al Momani M, Almomani BA, Masri AT. The clinical characteristics of primary headache and associated factors in children: a retrospective descriptive study. Ann Med Surg (Lond). 2021; 65:102374. doi:10.1016/j.amsu.2021.102374 PMid:34026104 PMCid:PMC8121873

18. Raieli V, Eliseo M, Pandolfi E, La Vecchia M, La Franca G, Puma D. Recurrent and chronic headaches in children below 6 years of age. J Headache Pain. 2005; 6(3):135-142.doi:10.1007/s10194-005-0168-z PMid:16355294 PMCid:PMC3451630

19. Orr SL, Aube M, Becker WJ, Davenport WJ, Dilli E, Dodick DW, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35(3):271-284. doi:10.1177/0333102414535997 PMid:24875925

20. Uyur E, Eldeş Hacıfazlıoğlu N. Clinical features and EEG findings in pediatric migraine: a retrospective analysis of 148 patients. Cephalalgia Rep. 2025;8:25158163251371154. doi:10.1177/25158163251371154

21. Richer L, Billinghurst L, Linsdell MA, Russell K, Vandermeer B, Crumley ET, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016;(4).doi:10.1002/14651858.CD005220.pub2 PMid:27091010 PMCid:PMC6516975

22. Bamaga AK, Alqarni L, Alrefaei MI, Aljedani HZ, Ywsef KA, Yaseen HH, et al. Quality of life among pediatric and adolescent patients with migraine: a cross-sectional study. J Fam Med Prim Care. 2025;14(6):2452-2457. doi:10.4103/jfmpc.jfmpc_1904_24 PMid:40726685 PMCid:PMC12296298

23. Khan A, Liu S, Tao F. Current trends in pediatric migraine: clinical insights and therapeutic strategies. Brain Sci. 2025;15(3):280. doi:10.3390/brainsci15030280 PMid:40149800 PMCid:PMC11940401

24. Suliman O, Mahjoub E, Abutwaimah J, Abutwaimah A, Alhusayni M, Albader D, et al. Prevalence and clinical features of abdominal migraine in children: a systematic review. J Adv Med Med Res. 2025;37(6):64-76. doi:10.9734/jammr/2025/v37i65852

25. Brickman L, Mondok L. Migraine in children and adolescents. Pract Neurol. 2023;23:23-27.

26. Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019; 93(11):500-509. doi:10.1212/WNL.0000000000008105 PMCid:PMC6746206

27. Orr SL. The evidence for the role of nutraceuticals in the management of pediatric migraine: a review. Curr Pain Headache Rep. 2018; 22(5):37. doi:10.1007/s11916-018-0692-6 PMid:29619575

28. Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA.2013;310(24):2622-2630. doi:10.1001/jama.2013.282533 PMid:24368463 PMCid:PMC4865682

29. Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, et al. Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents. Headache. 2018; 58(10): 1658-1669. doi:10.1111/head.13414 PMid:30324723 PMCid:PMC6258331

30. Yu S, Guo A, Wang Z, Liu J, Tan G, Yang Q, et al. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial. J Headache Pain. 2024;25(1):57. doi:10.1186/s10194-024-01731-4 PMid:38627638 PMCid:PMC11020209